This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tecemotide
DrugBank Accession Number
DB12568
Background

Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Tecemotide

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Q7Y026G2CX
CAS number
221214-84-2

References

General References
Not Available
PubChem Substance
347911345
Wikipedia
Tecemotide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentBreast Cancer1
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentNeoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC)2
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRectal Carcinoma1
1, 2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
Not AvailableTerminatedTreatmentMultiple Myeloma (MM) / Non-Small Cell Lung Carcinoma (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 20, 2016 22:55 / Updated at February 21, 2021 18:53